Researcher in lab

Find clinical trials

Our clinical trial portfolio is one of the largest in the country. We have more than 700 clinical trials open across 30 clinical units.

Find Melbourne Sexual Health Centre research studies and clinical trials
Clear filter
647 clinical trials found
Clinical trials

CVAY736Q12201

A phase 2 study to evaluate the efficacy and safety of ianalumab in patients with primary immune thrombocytopenia (ITP) previously treated with at least two lines of therapy (NCT05885555)

Currently recruiting

CYPRESS

A Phase 3, Multi-center, Randomized Withdrawal and Long-Term Extension Study of Ampreloxetine for the Treatment of Symptomatic Neurogenic Orthostatic Hypotension in Participants with Multiple System Atrophy (NCT05696717)

No longer recruiting

CYTB323A12101

Phase I/II, open label, multicenter study of YTB323 in adult patients with CLL/SLL, 3L+ DLBCL, ALL and 1L HR LBCL (NCT03960840)

Currently recruiting

CYTB323L12201

A Phase 2, randomized, open-label, controlled study to evaluate the efficacy and safety of rapcabtagene autoleucel versus comparator in participants with severe refractory idiopathic inflammatory myopathies (NCT06665256)

The CYTB323L12201 study is designed to evaluate the safety and efficacy of rapcabtagene autoleucel (CAR-T) compared to standard of care treatment in participants with idiopathic inflammatory myopathies (IIM). Participants will be randomised into either a CAR-T infusion or a comparator option. After the end of study participants who received the CAR-T infusion will enter a long-term follow-up period lasting up to 15 years.
Coming soon

CYTB323L12201

A Phase 2, randomized, open-label, controlled study to evaluate the efficacy and safety of rapcabtagene autoleucel versus comparator in participants with severe refractory idiopathic inflammatory myopathies (NCT06665256)

The CYTB323L12201 study is designed to evaluate the safety and efficacy of rapcabtagene autoleucel (CAR-T) compared to standard of care treatment in participants with idiopathic inflammatory myopathies (IIM). Participants will be randomised into either a CAR-T infusion or a comparator option. After the end of study participants who received the CAR-T infusion will enter a long-term follow-up period lasting up to 15 years.

Coming soon

CYTB323N12101

An open-label, multi-center, phase 1/2 study to assess safety, efficacy, and cellular kinetics of YTB323 in participants with Relapsing Multiple Sclerosis with breakthrough disease activity during previous treatment with a highly efficacious therapy (NCT06617793)

Currently recruiting

CYTB323R12101

An open-label, multi-center, phase I/II study to assess safety, disease progression, and cellular kinetics following YTB323 administration in participants with non-active Progressive Multiple Sclerosis [PMS] (NCT06675864)

Currently recruiting

D7400C00006

A Multicenter, Phase 1, Open-label, Dose-escalation and Expansion Study of AZD0486, a Bispecific Antibody Targeting CD19 in Subjects with Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma (NCT04594642)

Currently recruiting

D7405C00001

A Phase 1/2 Study to Evaluate the Safety and Efficacy of AZD0486 in Adolescent and Adult Participants with Relapsed or Refractory B-Cell Acute Lymphoblastic Leukaemia (NCT06137118)

Currently recruiting

DAPA_HF

Mechanisms of action of SGLT2 inhibitors in patients with heart failure with reduced ejection fraction (HFrEF) (ACTRN12621000187842)

Currently recruiting

Daratumumab@Home

A phase 2 study of the feasibility and efficacy of at home patient administered subcutaneous daratumumab in patients with relapsed multiple myeloma (ACTRN12624001468516)

Currently recruiting

DASL-HiCaP

DASL-HiCaP: Darolutamide Augments Standard Therapy for Localised Very High-Risk Cancer of the Prostate [ANZUP1801]. A randomised phase 3 double-blind, placebo-controlled trial of adding darolutamide to androgen deprivation therapy and definitive or salvage radiation in very high risk, clinically localised prostate cancer.

A randomised phase 3 double-blind, placebo-controlled trial of adding darolutamide to androgen deprivation therapy and definitive or salvage radiation in very high risk, clinically localised prostate cancer. 
Currently recruiting

DB in asthma

Targeted treatment for people with dysfunctional breathing and difficult asthma (ACTRN12624001285549)

Currently recruiting

DCD-HOPE

Hypothermic Oxygenated Perfusion (HOPE) in Donation after Circulatory Death (DCD) for Heart Transplantation (Registration Pending)

Coming soon

DECIDE

DExmedetomidine in Cardiac surgical Intraoperative Drug Evaluation (ACTRN12623001171606)

Currently recruiting

DEFINE

The effect of substantial weight loss with tirzepatide on heart failure with preserved ejection fraction in people with obesity (ACTRN12624000270516)

Coming soon

DEFiNE GPS

Distal Evaluation of Functional performance with Intravascular sensors to assess the Narrowing Effect: Guided Physiologic Stenting (short title: DEFiNE GPS) (NCT04451044)

Currently recruiting

DeLLphi-304

A Randomized, Open-label, Phase 3 Study of Tarlatamab Compared With Standard of Care in Subjects With Relapsed Small Cell Lung Cancer After Platinum-based First-line Chemotherapy (DeLLphi-304) (NCT05740566)

No longer recruiting

DeLLphi-308

A Phase 1b Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Preliminary Anti-Tumor Activity of Subcutaneous Tarlatamab in Subjects with Extensive Stage Small Cell Lung Cancer [DeLLphi-308] (NCT06598306)

Currently recruiting

DeLLphi-308

A Phase 1b Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Preliminary Anti-Tumor Activity of Subcutaneous Tarlatamab in Subjects with Extensive Stage Small Cell Lung Cancer [DeLLphi-308] (NCT06598306)

The primary objective of this study is to evaluate the safety and tolerability of subcutaneous (SC) tarlatamab.

Currently recruiting
9 10 11 12 13